Mateusz Hasso-Agopsowicz

Biographic Data

ID9022762
NAMEMateusz Hasso-Agopsowicz
GIVEN NAMESMateusz
FAMILY NAMEHasso-Agopsowicz
SIGNATUREHASSO-AGOPSOWICZ M
AFFILIATIONSWorld Health Organization
ORCID0000-0003-4137-4685
VERIFIEDYes
TOTAL WORKS6
TOTAL CITATIONS0
AUTHOR COUNT6
EDITOR COUNT0
FIRST PUBLICATION YEAR2022
LATEST PUBLICATION YEAR2026
H-INDEX0

  • Priority implementation research for measles-rubella microarray patches identified using the Child Health and Nutrition Research Initiative methodology

    Open AccessSara Sá Silva, Melissa Ko et al.ARTICLEJournal of Global Health2026

    Background: Measles and rubella continue to be a significant global health challenge, disproportionately impacting marginalised communities in low- and middle-income countries (LMICs). Innovative technologies such as measles-rubella microarray patches (MR-MAPs) are currently in development and can potentially improve immunisation coverage and equity through their unique product characteristics. Nonetheless, the limited evidence around their use c…

  • The global economic burden of antibiotic-resistant infections and the potential impact of bacterial vaccines

    Open AccessNichola R Naylor, Mateusz Hasso-Agopsowicz et al.ARTICLEBMJ Global Health2025

    INTRODUCTION: Antibiotic resistance (ABR) may increase hospital costs, utility loss and mortality risk per patient. Understanding these losses at national, regional and global scales is necessary for efficiently tackling ABR. Our aim is to estimate the global economic burden of antibiotic-resistant infections and the potential for bacterial vaccines to mitigate this burden. METHODS: We take healthcare system and labour productivity perspectives. …

  • Estimating the future global dose demand for measles–rubella microarray patches

    Open AccessMelissa Ko, Stefano Malvolti et al.ARTICLEFrontiers in Public Health2023

    Background: Progress toward measles and rubella (MR) elimination has stagnated as countries are unable to reach the required 95% vaccine coverage. Microarray patches (MAPs) are anticipated to offer significant programmatic advantages to needle and syringe (N/S) presentation and increase MR vaccination coverage. A demand forecast analysis of the programmatic doses required (PDR) could accelerate MR-MAP development by informing the size and return …

  • Exploring potential applications of measles and rubella microarray patches (MR-MAPs)

    Open AccessStefano Malvolti, Melissa Ko et al.ARTICLEFrontiers in Public Health2023

    Introduction: Innovative vaccine products will be critical in helping to address the existing implementation barriers that have prevented the achievement of the measles and rubella (MR) vaccine coverage targets. Overcoming those barriers will be necessary to achieve the "Immunization Agenda 2030" goals. Microarray patches (MAPs), an innovative needle-free delivery device currently in clinical development, can be a potential game changer in this r…

  • Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination

    Open AccessChaelin Kim, Marianne Holm et al.ARTICLEBMJ Global Health2023

    INTRODUCTION: Antimicrobial resistance (AMR) is a global health threat with 1.27 million and 4.95 million deaths attributable to and associated with bacterial AMR, respectively, in 2019. Our aim is to estimate the vaccine avertable bacterial AMR burden based on existing and future vaccines at the regional and global levels by pathogen and infectious syndromes. METHODS: We developed a static proportional impact model to estimate the vaccination im…

  • Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella

    Open AccessMateusz Hasso-Agopsowicz, Natasha S Crowcroft et al.ARTICLEFrontiers in Public Health2022

    Measles and rubella microarray patches (MR-MAPs) are critical in achieving measles and rubella eradication, a goal highly unlikely to meet with current vaccines presentations. With low commercial incentive to MAP developers, limited and uncertain funding, the need for investment in a novel manufacturing facility, and remaining questions about the source of antigen, product demand, and regulatory pathway, MR-MAPs are unlikely to be prequalified by…